The founder and MD of investment bank Candle Partners reflects on key pharma M&A trends over the years and the shape of things to come including private equity action and how family-owned firms are weighing monetization and diversification options.

Private equity firms are among those believed to be in the fray for a stake in India's Cipla, a company with a rich legacy and steeped in history. It’s an ideal case study for buyout funds, according to an investment banker.

Private equity firms are among those believed to be in the fray for a stake in India's Cipla, a company with a rich legacy and steeped in history. It’s an ideal case study for buyout funds, an investment banker tells Scrip.

Could more Indian firms consider re-aligning their US business amid heightened pricing and compliance pressures that have cast a shadow on the long-term viability of the generics segment? A cross section of experts including a senior executive at McKinsey & Co share their views on what to expect.